Cited 0 times in
Effects of N-3 polyunsaturated fatty acid supplement on inflammatory markers and insulin resistance in patients with the metabolic syndrome
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최현민 | - |
dc.date.accessioned | 2015-11-21T07:44:35Z | - |
dc.date.available | 2015-11-21T07:44:35Z | - |
dc.date.issued | 2009 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/125028 | - |
dc.description | Dept. of Medicine/석사 | - |
dc.description.abstract | [한글] [영문] N-3 polyunsaturated fatty acids (PUFA) supplement may be beneficial in patients with the metabolic syndrome (MS) through reduction of serum triglyceride (TG), systemic inflammation and insulin resistance. Recommendation dose of N-3 PUFA are 1 g/day for secondary prevention of myocardial infarction and 2-4 g/day for serum TG reduction. In the MS, there are few data regarding N-3 PUFA effect on the systemic inflammation and insulin resistance. Also, dose-dependent effects of N-3 PUFA on systemic inflammation and insulin resistance have never been evaluated. The goal of this study is to evaluate whether N-3 PUFA supplement may reduce systemic inflammation and insulin resistance in patients with the MS. We also investigate dose-dependent effects of N-3 PUFA on systemic inflammation and insulin resistance by comparing conventional (2 g/day) with high (4 g/day) dose of N-3 PUFA. Sixty patients with the MS were randomly enrolled in N-3 PUFA and placebo groups. Fifty-three (N-3 PUFA, N=26 and placebo, N=27) subjects completed this study. N-3 PUFA group received 2 g/day (conventional dose) for 6 weeks and 4 g/day (high dose) for another 6 weeks. We compared serum lipid and lipoprotein subclass profiles, inflammatory markers and insulin resistance between two groups. N-3 PUFA administration significantly reduced mean high sensitive C-reactive protein (hs-CRP; p = 0.01, repeated measures ANOVA) and homeostasis model assessment of insulin resistance (HOMA-IR; p = 0.03, repeated measures ANOVA) levels compared with placebo. N-3 PUFA mediated TG (p = 0.001, repeated measures ANOVA) and HOMA-IR (p = 0.000, repeated measures ANOVA) reduction were significantly related to dose-dependent effect of N-3 PUFA. However, there was no significant dose-dependent effect of N-3 PUFA on hs-CRP. In conclusion, N-3 PUFA administration in patients with the MS significantly reduced serum hs-CRP and insulin resistance compared with placebo. Especially, the improvement of insulin resistance was significantly related to dose-dependent effect of N-3 PUFA. | - |
dc.description.statementOfResponsibility | open | - |
dc.publisher | Graduate School, Yonsei University | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Effects of N-3 polyunsaturated fatty acid supplement on inflammatory markers and insulin resistance in patients with the metabolic syndrome | - |
dc.title.alternative | 대사 증후군 환자에서 N-3 다중 불포화 지방산 투여가 염증 표지 인자와 인슐린 저항성에 미치는 영향에 대한 연구 | - |
dc.type | Thesis | - |
dc.contributor.alternativeName | Choe, Hyun Min | - |
dc.type.local | Thesis | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.